SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Goldman Sachs Upgrades Vir Biotechnology to Buy, Raises Price Target to $54

Goldman Sachs upgrades Vir Biotechnology (NASDAQ:VIR) from Neutral to Buy and raises the price target from $48 to $54.

· 09/14/2020 05:04
Goldman Sachs upgrades Vir Biotechnology (NASDAQ:VIR) from Neutral to Buy and raises the price target from $48 to $54.